|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2007-6-6
|
|
pubmed:abstractText |
To investigate the magnitude of change in morning peak expiratory flow (PEF), asthma symptoms, and rescue beta2-agonist use, when the aim of treatment is to achieve guideline-defined control.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1471-4418
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
155-61
|
|
pubmed:meshHeading |
pubmed-meshheading:17551661-Adolescent,
pubmed-meshheading:17551661-Adult,
pubmed-meshheading:17551661-Aged,
pubmed-meshheading:17551661-Aged, 80 and over,
pubmed-meshheading:17551661-Albuterol,
pubmed-meshheading:17551661-Androstadienes,
pubmed-meshheading:17551661-Asthma,
pubmed-meshheading:17551661-Bronchodilator Agents,
pubmed-meshheading:17551661-Child,
pubmed-meshheading:17551661-Double-Blind Method,
pubmed-meshheading:17551661-Drug Combinations,
pubmed-meshheading:17551661-Endpoint Determination,
pubmed-meshheading:17551661-Female,
pubmed-meshheading:17551661-Humans,
pubmed-meshheading:17551661-Male,
pubmed-meshheading:17551661-Middle Aged,
pubmed-meshheading:17551661-Peak Expiratory Flow Rate,
pubmed-meshheading:17551661-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Improvement in asthma endpoints when aiming for total control: salmeterol/fluticasone propionate versus fluticasone propionate alone.
|
|
pubmed:affiliation |
North West Lung Centre, Wythenshawe Hospital, Manchester, UK. ashley.woodcock@manchester.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
